OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Wearable Remote Patient Monitoring Devices	278
Reply	139
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	127
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	122
Developing a System for Best Performance for Cardiac Transplantation	121
Reply	109
Reply	108
Editorial Board	106
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	97
Opportunities for Change in Home Health Care in Heart Failure	96
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure	96
Correction	91
Clinical Implications of the P.V142I TTR Variant	85
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	84
Revisiting ICD Therapy for Primary Prevention	82
Full issue PDF	81
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	81
Curing Ourselves of Toxic Positivity for Hospital-at-Home	79
Long-Term Effects of Sotatercept on Right Ventricular Function	76
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	75
Are Most HFpEF “Phenotypes” Just Different Stages of the Same Disease?	74
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	73
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	71
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	67
Delivering Quadruple Therapy for Heart Failure With Reduced Ejection Fraction in a Customizable Polypill	66

Contemporary Trends in Heart Failure Mortality	65
From Loop Diuretics to Closed-Loop Decongestion	65
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	64
Predictors of Incident Heart Failure Diagnosis Setting	64
Eating to Prevent Both Heart and Planetary Failure	63
Withdrawal of Guideline-Directed Medical Therapy in Heart Failure With Improved Ejection Fraction	62
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	59
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	57
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	57
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy	55
Associations Between Urinary Metal Levels and Incident Heart Failure	53
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	52
Challenges Addressing Prognosis in Advanced Heart Failure	52
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	50
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	48
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension	48
NT-proBNP	48
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	48
Reply	47
Prognosis for Acute Myocarditis	47
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	47
High NT-proBNP in Heart Failure	47
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	47
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	46
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	46
From Dispensing Pills to Building Pillars	45
Full Issue PDF	45
Compensation Models in Heart Failure	45
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	44
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	43
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	42
A Woman's Work Is Never Done	42
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	40
STRONG-HF	40
Heart Failure With Preserved Ejection Fraction	39
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	38
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF	38
Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension	38
The Path Toward a More Equitable Transplant System	38
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	37
Body Composition and Survival in Patients With Heart Failure	37
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	37
GDF-15 in Cardiovascular Disease	35
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	35
CD36 Loss-of-Function and Association With Dilated Cardiomyopathy	35
Advanced Heart Failure in the Cardiac Intensive Care Unit	35
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction	34
Heart Failure in Women	33
Genetically Proxied Interleukin-6 Signaling Inhibition and Heart Failure Risk	33
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	33

Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	33
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	33
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	32
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials	32
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	32
Racial and Genetic Differences	32
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	31
Higher Emergency Department Diuretic Dosing for Acute Heart Failure Associated With Lower Risk of Hospitalization	31
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	31
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	31
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	30
Management of Heart Failure–Related Cardiogenic Shock	30
Reply	30
Therapeutic Options in Ambulatory Advanced Heart Failure	29
Upper Body Hypoxemia During ECMELLA	29
REPLY	29
Policy Changes for Progress	29
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	29
Reevaluating Growth Hormone Therapy in HFrEF	29
Every Journey Needs a Guide	29
Risk Factors and Temporal Trends of Maternal Heart Failure	29
Rethinking Lifelong Management of Heart Failure Care in Young Adults	29
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	29
Geographic Variation in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	28
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	28
Understanding and Investigating Sex-Based Differences in Heart Transplantation	28
Facts and Fallacies of Body Composition Analysis in Heart Failure	28
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	28
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	28
Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients	27
Smoking Cessation Reduces the Risk of Heart Failure	27
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	27
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	27
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	27
Tafamidis in Octogenarians	27
Diabetes Therapy With SGLT2i After Heart Transplant	27
Obesity and Weight Loss Strategies for Patients With Heart Failure	27
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	27
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	27
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	27
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022	27
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	26
Full issue PDF	26
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	26
Instructions for Authors	26
Jump Starting the Heart	26
Setting the Diagnosis of Heart Failure	26
Critical Importance of Genetic Screening in Family Members	26
Full issue PDF	25
Venting the Venous Circulation	25
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	25
Redefining Pre–Heart Failure With Cardiac Biomarkers	25
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	25
Isolating Noise From Signals in the Air	24
Expanded Definition of Worsening Heart Failure	24
Editorial Board	24
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	24
From Better Models to Better Care	24
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	24
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	24
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	23
To Infinity and Beyond	23
Beyond Coronary Atherosclerosis	23
Heart Replacement Therapy	23
Moving From Prompts to Praxis With Remote Monitoring	23
Unreliable HFpEF Diagnosis by H2FPEF in AF	23
Genotype Predicts Heart Failure Independent of LVEF, Peak VO2, and NT-proBNP Levels in Hypertrophic Cardiomyopathy	22
Illuminating a Hidden Risk	22
Treatment of Obesity in Heart Failure	22
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	22
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	22
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	22
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	22
Severe Myocarditis Increase in Children Associated With Parvovirus B19 Infection	22
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	22
Global Heart Failure Trends in Young Adults	21
Secondary Mitral Regurgitation Trajectories and Prognosis With Intensification of Guideline-Directed Medical Therapy in Heart Failure	21
All That Glitters Is Not Gold	21
Full Issue PDF	21
HFpEF Scores	21

Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	21
Bereavement and Mortality in Heart Failure	20
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	20
Diet and Heart Failure	20
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	20
Correction	20
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	20
Istaroxime in HFpEF	20
Physical Activity Trajectories Preceding Incident Heart Failure	20
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	20
Reply	20
The Link Between Heart Failure and Neurodegeneration	20
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	20
Deactivation of Left Ventricular Assist Devices at the End of Life	19
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	19
Artificial Intelligence to Extract Structured Details From Unstructured Medical Records in a Global Heart Failure Trial	19
Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure	19
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	19
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	19
REPLY	19
Articulating the JACC Journals’ Direction in Times of Global Change	19
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	19
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	19
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	18
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	18
Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis	18
Impact of Female Sex on Cardiogenic Shock Outcomes	18
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	18
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	18
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure	18
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	18
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	17
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	17
Shedding Light on the Darkness of MYH7 Cardiomyopathies	17
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	17
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	17
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	17
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	17
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	17
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	17
Reply	16
Thin Evidence, Heavy Need	16
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	16
Correction	16
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	16
Low Serum Ferritin Might Predict Incident Heart Failure	16
Full issue PDF	16
Targeting Inflammation in Heart Failure Prevention	16
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	15
Aging in Heart Failure	15
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	15
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	15
Navigating the Global Burden of Pulmonary Arterial Hypertension	15
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	15
Reducing Pediatric Heart Failure Readmissions	15
Medication Optimization Clinic	15
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	15
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	15
Contemporary American and European Guidelines for Heart Failure Management	15
Exercise-Induced Versus Resting Left Atrial Hypertension	15
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	15
The Enigma of Natriuretic Peptides	15
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	15
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	15
Iron Deficiency Definition and Management in Patients With Heart Failure	14
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	14
Better 3 Hours Too Soon Than 1 Minute Late	14
Information for Authors	14
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	14
Redefining Boundaries in Heart Failure Care	14
Reply	14
Coronary Artery Disease Is Still a Major Cause of Heart Failure	14
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	14
Correction	14
The HeartMate 3 Risk Score	14
Reflections on Early Rehabilitation in Acute Heart Failure	14
BMI in HFpEF	14
Full issue PDF	13
Can Sensor Implantation Alone Reduce Heart Failure Hospitalizations Without Need for Structured Management Based on its Data?	13
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	13
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	13
REPLY	13
Safety and Feasibility of IVC Flow Modulation With the Doraya in Acute Decompensated Heart Failure	13
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	13
Pregnancy as a Sentinel Event	13
From Fuel to Flow	13
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	13
Echo-Based, Artificial Intelligence Algorithm Identifies Future Heart Failure Cases	13
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	13
Association of Extracoronary Calcification and Incident Heart Failure in the Multiethnic Study of Atherosclerosis (MESA)	12
Encouraging Data Encourage More Research on Optimal Medical Therapy for Patients With HFrEF	12
Balancing Efficacy and Safety With Finerenone in Patients With Heart Failure and Chronic Kidney Disease	12
Officers Page	12
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	12
Barriers and Facilitators to Prescribing Guideline-Directed Medical Therapy for Heart Failure in the Indian Health Service	12